糖基因ST8SIA4在人慢性粒细胞白血病多药耐药中的作用研究  

The correlation study of the glycogene ST8SIA4 in the multidrug resistance of human chronic myeloid leukemia

作　　者：张兆海 张瑞红 

机构地区：[1]辽宁省本溪市金山医院检验科,117000 [2]辽宁省本溪钢铁集团总医院手术室,117000

出　　处：《重庆医学》2015年第36期5074-5076,共3页Chongqing medicine

摘　　要：目的通过研究糖基因ST8SIA4在人慢性粒细胞白血病(CML)细胞株KCL22及其耐阿霉素(ADR)细胞株KCL22/ADR、CML患者外周血单个核细胞(PBMC)中表达的差异,明确糖基因ST8SIA4与人CML多药耐药的相关性。方法采用RT-PCR和Western Blot检测糖基因ST8SIA4在人CML及其耐药细胞株、CML及CML耐药患者PBMC中的表达;特异性下调糖基因ST8SIA4,检测干扰前、后CML细胞在体外对化疗药物的敏感性。结果糖基因ST8SIA4在人CML及其耐药细胞株、CML患者PBMC中表达水平比较差异有统计学意义(P<0.05);特异性下调ST8SIA4的表达,增加了KCL22/ADR细胞体内、体外的药敏性(P<0.05)。结论人CML细胞株及CML患者PBMC中糖基因ST8SIA4的表达差异有统计学意义,这些特征性改变与CML多药耐药具有相关性。Objective To investigate the differential expression of ST8SIA4 in the both chronic myeloid leukemia（CML）cell lines KCL22 and adriamycin resistant cell lines KCL22/ADR,peripheral blood mononuclear cells（PBMC）of CML patients,to clarify the correlation of ST8SIA4 and multidrug resistance of CML.Methods Using real-time PCR and Western blot for quantification of ST8SIA4,we compared the differential expression of ST8SIA4 in CML cell lines and PBMC of CML patients.The differentially expressed ST8SIA4 gene was silenced,and the chemosensitivity to anti-tumor drugs was analyzed in vitro.Results ST8SIA4 was differentially expressed in CML cell lines and PBMC of CML patients（P〈0.05）.The altered level of ST8SIA4 was increased drugresistant phenotype of KCL22/ADR cells both in vitro and in vivo（P〈0.05）.Conclusion The expression of ST8SIA4 was different in CML cell lines and PBMC of CML patients,these characteristic alterations were associated with multidrug resistance in CML.

关 键 词：糖基因ST8SIA4 多药耐药 粒细胞白血病 慢性 

分 类 号：R733.72[医药卫生—肿瘤]